Clinical Trial Data Sharing: IOM Envisions Open And Closed Doors
This article was originally published in The Pink Sheet Daily
Institute of Medicine report calls for greater, faster availability of full clinical trial data sets, but with no authority and many loopholes, impact on status quo may be minimal.
You may also be interested in...
GlaxoSmithKline, Pfizer, and Biogen are among those participating in new data-sharing and analytics platform; 2,500 trials currently available to researchers.
Focusing on orphan-first drugs may be best route to address pricing concerns, Health Affairs study suggests after finding that just one-fifth of spending on 15 top-selling partial orphan drugs was for the drugs’ rare disease indications.
US Remains Conservative On Vaccine Dosing Regimens As CDC’s ACIP Highlights Minimal Comfort With Relying On Unproven Correlates
The Center for Disease Control and Prevention’s Advisory Committee on Immunization Practices concerns about making COVID-19 vaccine dose regimen changes based on unproven immune correlates of protection could be a warning sign to sponsors about roadblocks they might face if updating vaccines to address viral variants or conducting pediatric studies relying on such surrogate endpoints.